Romidepsin

TargetMol
Product Code: TAR-T6006
Supplier: TargetMol
CodeSizePrice
TAR-T6006-1mg1mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-2mg2mg£194.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-5mg5mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-10mg10mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-25mg25mg£591.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-50mg50mg£811.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6006-100mg100mg£1,075.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas.
CAS:
128517-07-7
Formula:
C24H36N4O6S2
Molecular Weight:
540.69
Pathway:
DNA Damage/DNA Repair; Apoptosis; Chromatin/Epigenetic
Purity:
0.9967
SMILES:
CC=C1/NC(=O)[C@H]2CSSCCC=C[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
Target:
Apoptosis; HDAC

References

Sun L, Wan A H, Yan S, et al.A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.Acta Pharmaceutica Sinica B.2023 Zhao Y, Guo Y, Sun M, et al. Selenium-sensitive histone deacetylase 2 is required for forkhead box O3A and regulates extracellular matrix metabolism in cartilage. Journal of Bone and Mineral Metabolism. 2022: 1-13. Sasakawa Y, et al. Biochem Pharmacol, 2002, 64(7), 1079-1090. Kwon HJ, et al. Int J Cancer, 2002, 97(3), 290-296. Sandor V, et al. Br J Cancer, 2000, 83(6), 817-825. Furumai R, et al. Cancer Res, 2002, 62(17), 4916-4921. Blagosklonny MV, et al. Mol Cancer Ther, 2002, 1(11), 937-941. Sun WJ, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017 Mar 1;127:90-100.